RCYC
PFE icon

Richard C. Young & Co’s Pfizer PFE Stock Holding History

Richard C. Young & Co’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73K Sell
113,356
-15,456
-12% -$404K ﹤0.01% 101
2026
Q1 		$3.62M Sell
128,812
-68,246
-35% -$1.82M 0.3% 61
2025
Q4 		$4.91M Sell
197,058
-249,359
-56% -$6.29M 0.44% 57
2025
Q3 		$11.4M Buy
446,417
+2,741
+0.6% +$67.7K 1.06% 42
2025
Q2 		$10.8M Buy
443,676
+10,035
+2% +$234K 1.06% 44
2025
Q1 		$11M Buy
433,641
+676
+0.2% +$17.7K 1.18% 42
2024
Q4 		$11.5M Sell
432,965
-19,042
-4% -$517K 1.25% 37
2024
Q3 		$13.1M Buy
452,007
+12,818
+3% +$374K 1.43% 35
2024
Q2 		$12.3M Buy
439,189
+21,683
+5% +$597K 1.49% 34
2024
Q1 		$11.6M Buy
417,506
+224,125
+116% +$6.22M 1.45% 36
2023
Q4 		$5.57M Sell
193,381
-198,456
-51% -$6M 0.75% 55
2023
Q3 		$13M Buy
391,837
+2,125
+0.5% +$75.1K 1.85% 21
2023
Q2 		$14.3M Buy
389,712
+7,941
+2% +$309K 1.96% 21
2023
Q1 		$15.6M Sell
381,771
-1,838
-0.5% -$79.4K 2.15% 14
2022
Q4 		$19.7M Sell
383,609
-1,504
-0.4% -$72.1K 2.62% 7
2022
Q3 		$16.9M Buy
385,113
+342
+0.1% +$16.6K 2.58% 8
2022
Q2 		$20.2M Buy
384,771
+4,676
+1% +$238K 2.61% 8
2022
Q1 		$19.7M Sell
380,095
-7,076
-2% -$367K 2.51% 9
2021
Q4 		$22.9M Buy
387,171
+5,662
+1% +$281K 2.88% 7
2021
Q3 		$16.4M Sell
381,509
-1,529
-0.4% -$67.7K 2.25% 12
2021
Q2 		$15M Buy
383,038
+10,839
+3% +$422K 1.91% 15
2021
Q1 		$13.5M Buy
372,199
+25,047
+7% +$889K 1.79% 19
2020
Q4 		$12.8M Sell
347,152
-4,551
-1% -$167K 1.95% 17
2020
Q3 		$12.2M Buy
351,703
+122,518
+53% +$4.3M 1.97% 18
2020
Q2 		$7.11M Sell
229,185
-817
-0.4% -$27.8K 1.18% 34
2020
Q1 		$7.12M Buy
230,002
+22,535
+11% +$768K 1.38% 33
2019
Q4 		$7.71M Buy
207,467
+108,114
+109% +$3.85M 1.28% 40
2019
Q3 		$3.39M Sell
99,353
-107,422
-52% -$3.91M 0.61% 53
2019
Q2 		$8.5M Buy
206,775
+2,548
+1% +$101K 1.61% 26
2019
Q1 		$8.23M Buy
+204,227
New +$8.18M 1.57% 26

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Richard C. Young & Co's PFE Position: Q2 2026 in Review

Richard C. Young & Co reduced its Pfizer (PFE) stake by 12% in Q2 2026, selling an estimated $404K and leaving 113,356 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #101.

Richard C. Young & Co first reported a position in PFE in Q1 2019 and has held it in 30 quarters since. The position peaked at $22.9M in Q4 2021. 1,114 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Richard C. Young & Co held 113,356 shares of Pfizer worth $2.73K as of Q2 2026.
  • Richard C. Young & Co sold 15,456 Pfizer shares in Q2 2026, an estimated $404K.
  • Pfizer made up ﹤0.01% of Richard C. Young & Co's portfolio in Q2 2026, its #101 holding.
  • Richard C. Young & Co first reported a position in Pfizer in Q1 2019 and has held it in 30 quarters since.
  • Richard C. Young & Co's Pfizer position peaked at $22.9M in Q4 2021.
  • 1,114 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Richard C. Young & Co's 13F filing for Q2 2026, filed 28 Jul 2026.